DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

Issue 02 · Volume 41 · March 2015 DOI: 10.1055/s-005-28719 Anticoagulant Therapy: Present and Future Guest Editor: Job Harenberg, MD.

Preface

  • 109
  • 113
    Agnelli, Giancarlo; Prandoni, Paolo; Di Minno, Giovanni; Cimminiello, Claudio; Scaglione, Francesco; Boracchi, Patrizia; Molteni, Mauro; Polo Friz, Hernan; Di Minno, Matteo Nicola Dario; Marano, Giuseppe:

    Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies

  • 133
    Prandoni, Paolo; Lensing, Anthonie W. A.; Prins, Martin H.; Pesavento, Raffaele; Piccioli, Andrea; Sartori, Maria T.; Tormene, Daniela; Milan, Marta; Vedovetto, Valentina; Noventa, Franco; Villalta, Sabina; Harenberg, Job:

    The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation

  • 141
  • 146
  • 154
    Prandoni, Paolo; Milan, Marta; Barbar, Sofia; Sarolo, Lucia; Piovella, Chiara; Pesavento, Raffaele; Bilora, Franca:

    Incidence of Arterial Embolism in Patients on Treatment with Old and New Anticoagulants for Venous Thromboembolism

  • 160
  • 166
    Zolfaghari, Shabnam; Harenberg, Job; Frölich, Lutz; Weiss, Christel; Wehling, Martin; Wild, Philip; Prochaska, Jürgen; Beyer-Westendorf, Jan; Koscielny, Jürgen; Lip, Gregory Y. H.:

    Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference

  • 178
  • 188
  • 195
  • 208
  • 228
  • 237
  • 244
    Gerber, Ursula; Hoß, Sebastian G.; Shteingauz, Anna; Jüngel, Eva; Jakubzig, Bastian; Ilan, Neta; Blaheta, Roman; Schlesinger, Martin; Vlodavsky, Israel; Bendas, Gerd:

    Latent Heparanase Facilitates VLA-4–Mediated Melanoma Cell Binding and Emerges As a Relevant Target of Heparin in the Interference with Metastatic Progression

  • 255
    Lippi, Giuseppe; Harenberg, Job; Mattiuzzi, Camilla; Favaloro, Emmanuel J.:

    Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI